<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215380</url>
  </required_header>
  <id_info>
    <org_study_id>GA&amp; PCO</org_study_id>
    <nct_id>NCT04215380</nct_id>
  </id_info>
  <brief_title>Effects of Gum Arabic Ingestion on Hormonal and Metabolic Changes in Patients With Polycystic Ovary Syndrome</brief_title>
  <acronym>GA&amp;PCO</acronym>
  <official_title>Effects of Gum Arabic Ingestion on Hormonal and Metabolic Changes in Patients With Polycystic Ovary Syndrome: Two Arm Randomized Double Blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lamis Kaddam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al-Neelain University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effects on hormonal and metabolic changes in the PCOs patients after ingestion
      of Arabic gum
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) affects 5-20% of women of reproductive age worldwide it
      increases the risk for type 2 diabetes mellitus, cerebrovascular and cardiovascular events
      and not to mention it is one of the main causes of infertility. in the management of PCOS
      life style modification like weight reduction is necessary and recently it was discovered
      that GA ingestion causes significant reduction in BMI and body fat percentage among healthy
      adult females.so if GA could also affect the hormones and the metabolic changes in PCOs is
      going to be useful in decreasing the comorbidities and even treating PCOs.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 25, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hormonal changes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure changes from the baseline values regarding LH, FSH, and testosterone level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic change Serum cholestrol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure decrease from the baseline values regarding serum cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic change HBA1C</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure decrease from the baseline values regarding HBA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass index</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure decrease from the baseline values regarding BMI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive 100% natural Gum Arabic provided in a powder form as 30-grams-dose for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be provided with pectin powder provided as two-gram-dose fo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acacia Senegal extract</intervention_name>
    <description>Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks</description>
    <arm_group_label>Intervention Group</arm_group_label>
    <other_name>(Gum Arabic)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pectin</intervention_name>
    <description>Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are diagnosed with PCO by independent Gynecologist

        Exclusion Criteria:

          -  Diabetic patients

          -  Menopausal women

          -  History of allergy to Gum Arabic
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imad M Fdl-Elmula, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alneelain University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banoon center for assisted reproduction and, obstetrics and gynecology</name>
      <address>
        <city>Khartoum</city>
        <zip>1113</zip>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <link>
    <url>http://www.banoonivf.net/index.php/2014-03-24-20-15-27</url>
    <description>Study facility</description>
  </link>
  <reference>
    <citation>Babiker R, Elmusharaf K, Keogh MB, Saeed AM. Effect of Gum Arabic (Acacia Senegal) supplementation on visceral adiposity index (VAI) and blood pressure in patients with type 2 diabetes mellitus as indicators of cardiovascular disease (CVD): a randomized and placebo-controlled clinical trial. Lipids Health Dis. 2018 Mar 20;17(1):56. doi: 10.1186/s12944-018-0711-y.</citation>
    <PMID>29558953</PMID>
  </reference>
  <reference>
    <citation>Esmaeilzadeh S, Andarieh MG, Ghadimi R, Delavar MA. Body mass index and gonadotropin hormones (LH &amp; FSH) associate with clinical symptoms among women with polycystic ovary syndrome. Glob J Health Sci. 2014 Sep 28;7(2):101-6. doi: 10.5539/gjhs.v7n2p101.</citation>
    <PMID>25716399</PMID>
  </reference>
  <reference>
    <citation>Kaddam L, Fadl-Elmula I, Eisawi OA, Abdelrazig HA, Saeed AM. Acacia Senegal (Gum Arabic) Supplementation Modulate Lipid Profile and Ameliorated Dyslipidemia among Sickle Cell Anemia Patients. J Lipids. 2019 Jun 18;2019:3129461. doi: 10.1155/2019/3129461. eCollection 2019.</citation>
    <PMID>31316836</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Al-Neelain University</investigator_affiliation>
    <investigator_full_name>Lamis Kaddam</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

